Obalon Therptcs (OBLN) Receives Average Rating of “Hold” from Analysts

Shares of Obalon Therptcs (NASDAQ:OBLN) have been given an average rating of “Hold” by the seven analysts that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $16.00.

A number of equities analysts have recently commented on the stock. Zacks Investment Research raised shares of Obalon Therptcs from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. UBS AG reissued a “buy” rating and issued a $20.00 price target (down previously from $22.00) on shares of Obalon Therptcs in a report on Wednesday, August 9th. Finally, Northland Securities reissued a “sell” rating and issued a $6.00 price target on shares of Obalon Therptcs in a report on Wednesday, August 2nd.

Shares of Obalon Therptcs (NASDAQ OBLN) opened at 10.06 on Friday. Obalon Therptcs has a 12 month low of $8.27 and a 12 month high of $15.30. The firm’s market cap is $169.25 million. The firm has a 50-day moving average of $9.87 and a 200-day moving average of $9.87.

Obalon Therptcs (NASDAQ:OBLN) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.03). The company had revenue of $1.96 million during the quarter, compared to the consensus estimate of $1.77 million. Obalon Therptcs had a negative return on equity of 108.07% and a negative net margin of 566.87%. On average, analysts anticipate that Obalon Therptcs will post ($1.86) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Obalon Therptcs (OBLN) Receives Average Rating of “Hold” from Analysts” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://transcriptdaily.com/2017/10/08/obalon-therptcs-obln-receives-average-rating-of-hold-from-analysts.html.

Several institutional investors have recently made changes to their positions in OBLN. UBS Group AG boosted its stake in shares of Obalon Therptcs by 90.8% in the 1st quarter. UBS Group AG now owns 11,856 shares of the company’s stock valued at $127,000 after purchasing an additional 5,641 shares in the last quarter. Blair William & Co. IL purchased a new stake in shares of Obalon Therptcs in the 2nd quarter valued at $134,000. California State Teachers Retirement System boosted its stake in shares of Obalon Therptcs by 53.5% in the 2nd quarter. California State Teachers Retirement System now owns 15,200 shares of the company’s stock valued at $151,000 after purchasing an additional 5,300 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Obalon Therptcs in the 1st quarter valued at $168,000. Finally, Teachers Advisors LLC boosted its stake in shares of Obalon Therptcs by 235.7% in the 2nd quarter. Teachers Advisors LLC now owns 17,621 shares of the company’s stock valued at $175,000 after purchasing an additional 12,372 shares in the last quarter. 44.97% of the stock is owned by institutional investors.

Obalon Therptcs Company Profile

Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.

Receive News & Ratings for Obalon Therptcs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therptcs and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply